Active substance

Results for the substance nirmatrelvir+ritonavir

1 result

About this active substance

Nirmatrelvir and ritonavir are used together as an antiviral treatment for COVID-19. Nirmatrelvir inhibits the main protease of SARS-CoV-2, preventing viral replication, while ritonavir boosts nirmatrelvir levels in the body by inhibiting its metabolism.

This combination is administered orally, usually twice daily for five days. It is indicated for patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease. Common side effects include diarrhea, nausea, and altered taste.

The treatment is contraindicated in patients with severe renal or hepatic impairment, as well as those taking medications that interact with ritonavir. Additionally, use during pregnancy should be carefully evaluated due to potential risks.

This combination represents a significant advancement in COVID-19 treatment, reducing the risk of hospitalization and death. It is essential that administration is done according to the physician's instructions and within a well-defined treatment plan.